Researchers have found that a peptide, called STAT6-IP, when delivered to the lungs of neonatal mice at the time of first RSV exposure reduces the development of allergic-type lung inflammation and airway hyperresponsiveness (‘twitchy’ airways) in mice when they are ‘re-challenged’ with RSV as young adults.